TB-500 for Hair Growth: What the Evidence Shows

TB-500 for hair growth has not been shown to regrow hair in people. The studies behind the claim used thymosin beta-4, a larger protein, in rats, mice, and laboratory cells. TB-500 is a short piece of that protein. A result for the whole molecule does not establish a result for the fragment.

That leaves an understandable question: why does TB-500 keep appearing in hair-loss discussions? There is real biology behind the interest. There is also a gap between that biology and a treatment tested on a human scalp.

TB-500 for hair growth starts with a different molecule

Thymosin beta-4 contains 43 amino acids, the building blocks of proteins. The TB-500 fragment contains seven, with a small chemical cap at one end. A 2012 analysis by Esposito and colleagues in Drug Testing and Analysis identified that fragment in material sold as TB-500.

The full protein interacts with actin, a protein that helps cells hold their shape and move. Researchers have studied how this relates to hair follicles, the small structures in skin where hairs grow. The site's thymosin beta-4 guide explains the parent and fragment in more detail.

The distinction is practical. A study needs to match the actual molecule before its findings can inform a prescription. Sharing part of a sequence does not establish the same effect, safety, or dose.

What the hair-follicle studies actually found

The frequently cited starting point is Philp and colleagues' 2004 FASEB Journal paper. Its abstract reports hair growth in normal rats and mice given full-length thymosin beta-4. It also describes cells isolated from rat whisker follicles.

Those cells moved and developed into more specialized cells in the presence of the protein. They were related to stem cells, cells that can produce other cell types, in the follicle's bulge region. The bulge is a pocket where these cells live. That helps explain the interest in hair growth without establishing a treatment for thinning hair.

A 2007 report by Philp and colleagues in Annals of the New York Academy of Sciences described rat and mouse models again. These included mice genetically changed to make more thymosin beta-4. It was not a human hair-loss trial or a test of the TB-500 fragment.

Later work continued along that animal pathway. In Gao and colleagues' 2015 PLOS One study, researchers removed hair from mice with different genetic changes. Mice making extra thymosin beta-4 reached a similar extent of regrowth at 11 days, compared with 13 days in ordinary mice. Mice lacking the gene took 16 days.

A 2016 Molecular Genetics and Genomics study also used genetically changed mice. It examined signals connected with blood-vessel growth and cell movement around follicles. This supports further study of the full protein. Changing a mouse's gene activity is a different experiment from prescribing a fragment to a person.

Has anyone tested it for human hair loss?

No published clinical trial has established hair regrowth with TB-500. The cited thymosin beta-4 experiments also do not establish a benefit for human scalp hair loss.

As of October 1, 2026, the day this article was written, a ClinicalTrials.gov search for hair studies returned no registered trial matching TB-500 or thymosin beta-4 with hair or alopecia, meaning hair loss. A registered TB-500 cardiovascular study concerns heart and blood-vessel markers, with no results posted. It does not answer the hair question.

A registry entry describes a planned study; it does not establish that treatment worked. Human hair research would need a diagnosed condition, a comparison group, measured scalp hair counts, and unwanted effects tracked over time.

What July's FDA review means for this question

As of October 1, 2026, the day this article was written, FDA's July 23, 2026 staff presentation reported no identified clinical studies or human exposure data for TB-500 by any route. It concerned wound healing and the 503A Bulks List, a federal list of raw ingredients for prescription compounding. It did not establish hair regrowth.

FDA also raised possible immune reactions involving peptide clumps and impurities. An immune reaction means the body's defenses respond to the medicine itself. The presentation did not establish how often that happens in people taking TB-500.

TB-500 is coming soon to Promise as a compounded medication, which is different from an FDA-approved product: the formulation Promise will offer is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor. The separate TB-500 FDA review covers the regulatory record.

The type of hair loss changes the conversation

Androgenetic alopecia means inherited pattern hair loss, where follicles gradually shrink. Telogen effluvium means excess shedding after more hairs enter their resting phase, often following illness, major stress, or weight loss. The American Academy of Dermatology explains both hereditary hair loss and excess shedding.

A clinician considers when thinning started, its pattern, scalp changes, recent health events, and current medicines. Those details can point toward different causes. Mouse regrowth after hair removal does not settle either diagnosis in a person.

Topical minoxidil has U.S. labeling for pattern hair loss, and oral finasteride has labeling for male pattern hair loss. The AAD treatment guide describes their uses and limits. Whether either fits belongs in the clinical conversation, alongside any peptide question.

Shedding during weight treatment has its own evidence and possible causes; semaglutide and hair loss covers that question. A new peptide does not replace evaluating why hair is being lost.

TB-500 vs GHK-Cu for hair

GHK-Cu is a three-amino-acid peptide bound to copper. Its hair evidence is a separate question, covered in the GHK-Cu hair guide.

A small controlled eyebrow serum study reported findings in 18 adults over 12 weeks. Eyebrows, a serum, and scalp hair loss are different settings. That study did not compare GHK-Cu with TB-500.

There is no established winner between these peptides for human scalp regrowth. Choosing by the number of positive-looking papers misses what matters: the actual molecule, condition, and preparation tested.

What a provider visit can clarify

A useful visit starts with the hair-loss timeline and diagnosis, then weighs current treatment, medical history, and the evidence for the proposed medicine. The conversation can also define how progress would be measured and how suspected side effects would be reviewed.

At Promise, a licensed provider reviews every request and may prescribe or decline; not everyone qualifies. Provider involvement creates an accountable decision and follow-up. It does not turn animal hair findings into established human regrowth.